Carcinoma, Basal Cell
Conditions
Keywords
Carcinoma, Basal Cell, Vismodegib, Radiotherapy
Brief summary
This is a Fleming-A' Hern, single arm, multicenter, no-profit, phase II study of radiotherapy and Vismodegib in adult patients with high risk or locally advanced basal cell carcinoma not amenable to radical surgery cell carcinoma (BCC) (comparator: not applicable). The recruitment period is expected to be approximately 24 months. The trial will consist of a Screening/Baseline period (Day -28 to -1), a Treatment Period when patients will be treated with radiotherapy (4 weeks) followed by Vismodegib 150 mg/die continuously for six cycles (24 weeks). The study will end 14 months after start of treatment of the last patient enrolled and evaluable according to primary end point.
Detailed description
This is a Fleming-A' Hern, single arm, multicenter, no-profit, phase II study of radiotherapy and Vismodegib in adult patients with high risk or locally advanced basal cell carcinoma not amenable to radical surgery cell carcinoma (BCC) (comparator: not applicable). The recruitment period is expected to be approximately 24 months. The trial will consist of a Screening/Baseline period (Day -28 to -1), a Treatment Period when patients will be treated with radiotherapy (4 weeks) followed by Vismodegib 150 mg/die continuously for six cycles (24 weeks). The study will end 14 months after start of treatment of the last patient enrolled and evaluable according to primary end point. The primary objective is to evaluate the activity of the study therapy (radiotherapy followed by six cycles of Vismodegib 150 mg/d continuously) in terms of proportion of patients progression free at 12 months. The secondary objectives are: to evaluate the efficacy of the study therapy in terms of progression free survival (PFS) and overall survival (OS); to assess the response in terms of overall response rate (ORR) (complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)); to assess duration of response (DoR); to assess the safety in terms of incidence, type, and severity of adverse events (AEs) and serious adverse events (SAEs) ;to measure the effects of skin disease on quality of life (QoL) of patients under therapy (Skindex-16)
Interventions
DRUGVismodegib
Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
RADIATIONRadiotherapy
Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
Sponsors
Istituto Clinico Humanitas
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written, signed informed consent 2. Age ≥ 18 years 3. Histopathologic confirmation that the lesion is BCC before enrollment 4. Patients with high risk of relapse BCC not undergone radical surgery, for which treating physician must consider the disease to be no more operable. 5. Clinical features defining high risk of relapse include infiltrative growth margins, size, tumor location, histological subtype (the morpheaform, the sclerosing, the infiltrating, the micronodular and the metatypical subtypes are associated with higher risk of relapse as compared to the risk associated with the superficial and the nodular types), recurrent-refractory tumors (see Table 1), basal cell carcinoma size (largest tumor diameter) ≤ 5 cm for head and neck tumors 6. Clinical features for definition of BCC not amenable for radical surgery include: * BCC that has recurred in the same location after minimum 2 surgical procedures (excluding biopsies) and/or curative resection is deemed unlikely * multifocal BCC or extensive tumors (see table 1) with bleeding or infected areas * anticipated substantial morbidity and/or deformity from surgery (e.g., removal of all or part of a facial structure, such as nose, ear, eyelid, eye; or requirement for limb amputation) 7. Patients with BCCs localized where surgery is technically difficult, or would result in unacceptable tissue destruction 8. Patients with a clinical contraindication to surgery 9. Previous radiotherapy on other BCC 10. Patients with measurable and/or non-measurable disease (as defined by RECIST, v1.1) are allowed 11. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 12. Adequate hematopoietic capacity, defined as the following: * Hemoglobin : 8.5 g/dl * Absolute neutrophil count (ANC) ≥ 1500/mL * Platelet count ≥ 75,000/mL 13. Adequate hepatic function, defined as the following: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN)Total bilirubin ≤ 1.5 × ULN or within 3 × ULN for patients with documented Gilbert syndrome. Adequate renal function, defined by calculated serum creatinine clearance (CrCl) ≥ 30 mL/min 14. For women of childbearing potential, a negative serum pregnancy test within 7days prior to commencement of dosing is required. 15. Women of child-bearing potential must use two methods of acceptable contraception including one highly effective method and a barrier method, as directed by their physician, during treatment and for at least 24 months after completion of study treatment. Highly effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (e.g., implants, injectables, combined oral contraception, or intra-uterine devices). At the discretion of the Investigator, acceptable methods of contraception may include total abstinence. Periodic abstinence (e.g., calendar, ovulation, symptothermal, and post ovulation methods) and withdrawal are not acceptable methods of contraception (See Appendix B). 16. For male patients with female partners of childbearing potential, agreement to use a condom, even after a vasectomy, during sexual intercourse with female partners while being treated with Vismodegib, and for 2 months after completion of study treatment 17. Agreement not to donate blood or blood products during the study and for at least 24 months after completion of study treatment (Vismodegib).
Exclusion criteria
1. Inability or unwillingness to swallow capsules 2. Inability or unwillingness to comply with study procedures 3. Pregnancy or lactation (lactation not allowed for at least 24 months after completion of study treatment) 4. Concurrent non-protocol-specified anti-tumor therapy (e.g., chemotherapy, other targeted therapy, photodynamic therapy, including participation in an experimental drug study) 5. Metastatic BCC 6. Gorlin Syndrome or any other contraindication to radiotherapy 7. Recent (i.e., within the past 28 days prior to enrollment in this study) or current participation in another experimental drug study 8. Uncontrolled medical illness, including advanced malignancies, at the discretion of the Investigator 9. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| evaluate the activity of the study therapy in terms of proportion of patients progression free | 1 years | The primary objective is to evaluate the activity of the study therapy (radiotherapy followed by six cycles of Vismodegib 150 mg/d continuously) in terms of proportion of patients progression free at 12 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| evaluate the efficacy of the study therapy in terms overall survival | 2 years | The secondary objectives are: to evaluate the efficacy of the study therapy in terms of overall survival (OS); |
| response in terms of overall response rate (ORR) | 2 years | to assess the response in terms of ORR (complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)) |
| evaluate the efficacy of the study therapy in terms of progression free survival | 2 years | The secondary objectives are: to evaluate the efficacy of the study therapy in terms of progression free survival (PFS) |
| assess the safety in terms of incidence, type, and severity of adverse events (AEs) and serious adverse events (SAEs) | 2 years | to assess the safety in terms of incidence, type, and severity of AEs and SAEs |
| measure the effects of skin disease on quality of life (QoL) of patients | 2 years | to measure the effects of skin disease on quality of life (QoL) of patients under therapy (Skindex-16) |
| duration of response | 2 years | to assess duration of response (DoR); |
Countries
Italy
Outcome results
None listed